PARP1 and Ewing sarcoma: Since the 1990’s it has been known that Ewing sarcomas express high levels of PARP-132, and the premise of PARP inhibition as a therapeutic avenue for the treatment of Ewing sarcoma has been furthered strengthened by several key studies.